Sequent Scientific’s arm to acquire animal health business of Lyka Exports

28 Aug 2015 Evaluate

Sequent Scientific’s arm Alivira Animal Health has entered into a definitive agreement with Lyka Exports, a subsidiary of Lyka Labs, under which Alivira will acquire the animal health business of Lyka Exports on a going concern basis. DSK Legal acted as the legal advisor for the transaction on behalf of Alivira. Lyka was advised by Ernst & Young, as the M&A Advisor and PDS Legal as the Legal Advisor.

The parties expect the transaction to close in next 6 weeks subject to customary closing conditions including shareholders’ approval of Lyka. The proposed acquisition of Lyka’s animal health business includes all IPRs, Sales/ Marketing/Distribution network with related employees, contracts, assets and liabilities.

In FY15, Lyka’s animal health business registered a top line of close to Rs 23.50 crore with EBITDA margins in the range of 12%. The business is growing by over 30% during the ongoing financial year (FY16).

Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. Sequent is the world's largest producer of Anthelmintics and by far the strongest player in the Veterinary API business.


Sequent Scientific Share Price

199.65 -8.00 (-3.85%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×